UK genome analysis has important implications for COVID-19 clinical trials

Scientists at the University of Bristol who have been sequencing the genetic material from SARS-CoV-2 — the virus that causes COVID-19 — have highlighted important implications for scientists around the world conducting vaccine trials aimed at preventing the disease. The findings are published on the preprint site bioRxiv.
Source: University of Bristol news - Category: Universities & Medical Training Tags: International, Research; Faculty of Life Sciences, Faculty of Life Sciences, School of Cellular and Molecular Medicine; Press Release Source Type: news

Related Links:

Authors: Stefano ML, Kream RM, Stefano GB Abstract The emergence of the novel ß-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic of coronavirus disease 2019 (COVID-19). Clinical studies have documented that potentially severe neurological symptoms are associated with SARS-CoV-2 infection, thereby suggesting direct CNS penetration by the virus. Prior studies have demonstrated that the destructive neurological effects of rabies virus (RABV) infections are mediated by CNS transport of the virus tightly bound to the nicotinic acetylcholine receptor (nACh...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
00:59 Chloroquine on rocky groundPresident Trump's preferred coronavirus treatment is the focus of a new study suggesting it could cause more harm than good, but not everybody agrees. We discuss the fallout as trials around the world are paused and countries diverge over policy advice.News: India expands use of controversial coronavirus drug amid safety concernsNews: Safety fears over hyped drug hydroxychloroquine spark global confusion12:12 Are we rushing science?Coronavirus papers are being published extremely quickly, while normally healthy scientific debate is being blown up in the world’s press. Is there a ...
Source: Nature Podcast - Category: Science Authors: Source Type: podcasts
CONCLUSIONS: This new disease is pushing the scientific community to develop swiftly a safe and effective vaccine. Notwithstanding the limitations of our analysis, given by the absence of available results, we try to provide a comprehensive view of the ongoing clinical trials in humans. Our analysis reveals a worldwide effort of both scientists and enterprises to achieve one of the most challenging goals of our century. PMID: 32456404 [PubMed - as supplied by publisher]
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research
Conclusions: The outbreak of the epidemic could promote coronavirus research, meanwhile, coronavirus research contributes to overcoming the epidemic. Attention should be drawn to the latest popular research, including “Spike protein,” “Receptor binding domain,” and “Vaccine.” Therefore, more and more efforts will be put into mechanism research and vaccine research and development, which can be helpful to deal with the epidemic.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
Small animal models (mice, ferrets, hamsters) are essential for understanding how SARS-CoV-2 causes disease and for pre-clinical evaluation of vaccines and antiviral therapeutics. One promising model has been developed by modifying SARS-CoV-2 so that it binds to murine ACE2. Laboratory mice cannot be infected with SARS-CoV-2 because the viral spike glycoprotein (illustrated) does not bind […]
Source: virology blog - Category: Virology Authors: Tags: Uncategorized ACE2 antiviral coronavirus COVID-19 mouse model SARS-CoV-2 spike glycoprotein vaccine virology viruses Source Type: blogs
Condition:   SARS-CoV-2 Interventions:   Biological: Biological: mRNA-1273: 50 mcg;   Other: Placebo;   Biological: Biological: mRNA-1273: 100 mcg Sponsors:   ModernaTX, Inc.;   Biomedical Advanced Research and Development Authority Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Just a couple of short months ago, workplace safety was a familiar concept. The potential hazards — exposure to chemicals, proximity to machinery, ladders, and so forth — and the preventive measures implemented by employers were straightforward and well-understood. What does that look like in the COVID-19 era? Social distancing . . . temperature checks . . . obsessive hand washing . . . face masks and shields . . . double and triple shifts to comply with strict capacity requirements. And that bulletin board where the company proudly touted the number of days without a workplace injury? N...
Source: MDDI - Category: Medical Devices Tags: Business Source Type: news
The COVID-19 pandemic has had significant global consequences, with healthcare systems stretched to their limits, a growing death toll, and economic devastation as economies came grinding to a halt. The pandemic and its aftereffects will be with u...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Medicine Public Health Source Type: blogs
The novel coronavirus (COVID-19) outbreak has rapidly spread across the world. As medical systems continue to develop vaccines and treatments, it is crucial for the public health community to establish nonpharmaceutical interventions (NPIs) that can effectively mitigate the rate of SARS-Coronavirus-2 (SARS-CoV-2) spread across highly populated residential areas, especially among individuals who have close contact with confirmed cases. A community-driven preparedness strategy has been implemented in metropolitan areas in China. The Chinese Center for Disease Control and Prevention (CCDC) has required that all COVID-19 confi...
Source: Journal of Public Health Management and Practice - Category: Health Management Tags: Research Reports: Practice Brief Report Source Type: research
In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently investigating potential medications to treat COVID-19. The immunosuppressed status of some cancer patients (whether caused by the dis...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Review Article Source Type: research
More News: Clinical Trials | COVID-19 | Genetics | SARS | Universities & Medical Training | Vaccines